Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialPaolo A. Ascierto, Vanna Chiarion‐Sileni, Piotr Rutkowski et al.|Journal of Clinical Oncology|2022Cited by 231
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trialPaolo A. Ascierto, Giuseppe Palmieri, Milena Casula et al.|Nature Communications|2024Cited by 94